Yale Targets COVID-19 with Innovative Computational Design Methods
Yale scientists have developed a new class of antiviral agents that shows promise for creating COVID-19 therapeutics — exhibiting particular effectiveness when used in tandem with the drug remdesivir, another antiviral medication approved for use against the virus.Source: YaleNews
Taking a Dumbbell to Drug-Resistant Cancers
The hope is that PROTACs can treat other “undruggable” cancers that don’t respond to current treatments, including types of lung, breast, and colorectal cancers that may not have an active site on which a small-molecule drug or monoclonal antibody could bind.
Diverse Junior Scientists Display Their Talents and Learn to Navigate Academia
The fellows largely represented communities that have been historically unrepresented in the field of medical research, including those from ethnic and racial minorities, those with disabilities, those from low socioeconomic backgrounds, women, or those who identify as LGBTQI+.
Two YSM Faculty Receive International Cytokine & Interferon Society Young Investigator Awards
Yale School of Medicine (YSM) Assistant Professors of Immunobiology Carrie Lucas, PhD, and Aaron Ring, MD, PhD, recently received Young Investigator Awards from the International Cytokine & Interferon Society (ICIS).
Winners Announced for Annual Yale Cancer Center Conclave Awards
Yale Cancer Center held its annual Conclave award ceremony virtually on January 26th to celebrate faculty and provider accomplishments 2020. Faculty and staff were honored with clinical and research prizes including the Ruth McCorkle Oncology Advanced Practice Provider Award, the Class of ‘61 Cancer Research Award, and the Yale Cancer Center Lifetime Achievement Award.
Yale Postdoc Wins First Cell Press Rising Black Scientists Award
Chrystal Starbird, a postdoctoral fellow who works in the Ferguson Lab at the Yale Cancer Biology Institute, recently won the first Cell Press Rising Black Scientists Award. Her winning essay detailing her experiences as a person from an underrepresented group in science will be published in the February issue of the journal Cell.Source: Yale Daily News
A Class Act
The Yale Class of 1961 Cancer Center Endowment provides generous support for some of Yale Cancer Center’s most promising scientists. The legacy from the Yale Class is the Yale Class of 1961 Cancer Center Endowment. Established in 2016, the Endowment, which stands at more than $1.5 million and continues to grow, has honored one Yale Cancer Center faculty member each year since its inception with a $50,000 grant to support their highly promising cancer research.
Yale Psychiatry Names New Research Leaders at Connecticut Mental Health Center
Marina Picciotto, PhD, Deputy Chair for Basic Science and Charles B.G. Murphy Professor of Psychiatry, of Neuroscience, of Pharmacology and in the Child Study Center, has been named Director of the Ribicoff Labs and of the Division of Molecular Psychiatry. Christopher Pittenger, MD, PhD, Professor of Psychiatry, Assistant Chair for Translational Research, and Director of the Yale OCD Research Clinic, has been named Director of the Clinical Neuroscience Research Unit (CNRU) and of the Neuroscience Research Training Program (NRTP).
Understanding Immune System Blunders in Response to the Coronavirus
Genetics, gender, and even botched timing on the part of the immune response all appear important in the development of COVID-19. Akiko Iwasaki, PhD, is leading research to help us better predict who is likely to sail through a bout with COVID-19 and who may need targeted lifesaving care.
Carrie Lucas, PhD and Aaron Ring, MD, PhD are winners of two 2020 International Cytokine & Interferon Society Young Investigator Awards
Carrie Lucas, PhD and Aaron Ring, MD, PhD are winners of two 2020 International Cytokine & Interferon Society Young Investigator Awards—the Christina Fleischmann Award to Young Women Investigators and the Milstein Young Investigator Award, respectively.Source: The International Cytokine & Interferon Society (ICIS)
Yale Study Leads to FDA Approval of Drug to Treat Non-small Cell Lung Cancer
Based on results of a clinical trial led by Yale Cancer Center researchers, the U.S. Food and Drug Administration has approved osimertinib for the treatment of adults with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations, which occurs in about 10 percent of patients.
Roy S. Herbst, MD, PhD, Receives 2020 ACCC Clinical Research Award
Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, has been selected as the 2020 Clinical Research Award recipient by the Association of Community Cancer Centers for significantly and positively impacting oncology patients, their families, and the broader oncology community.